Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3-Reference-Cited by-同舟云学术

Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3

Published:2015-01 Issue:4 Volume:456 Page:908-912
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Kamada Haruhiko^ORCID,Taki Shintaro,Nagano Kazuya,Inoue Masaki,Ando Daisuke,Mukai Yohei,Higashisaka Kazuma,Yoshioka Yasuo,Tsutsumi Yasuo,Tsunoda Shin-ichi

Funder

JSPS KAKENHI

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference14 articles.

1. Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis;Aasheim;Biochim. Biophys. Acta,2005

2. Dancing with the dead: Eph receptors and their kinase-null partners;Truitt;Biochem. Cell Biol.,2011

3. Eph receptor A10 has a potential as a target for a prostate cancer therapy;Nagano;Biochem. Biophys. Res. Commun.,2014

4. Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients;Nagano;Cancer Med.,2013

5. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers;Nagano;J. Control. Release,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert “Cold” Tumors to “Hot” Tumors;International Journal of Molecular Sciences;2024-06-29

2. Advances in immunotherapy for triple-negative breast cancer;Molecular Cancer;2023-09-02

3. Bispecific Antibodies in Targeted Cancer Immunotherapy;Handbook of Cancer and Immunology;2023

4. Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology;Pharmaceutics;2022-07-29

5. Recent progress in antibody-based therapeutics for triple-negative breast cancer;Expert Opinion on Drug Delivery;2022-07-03